Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida플로리다의 암 환자에서 SARS-CoV-2 mRNA-1273 백신 접종에 대한 항체 반응 평가Article Published on 2022-05-012022-09-12 Journal: JAMA Oncology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI age anti-CD20 anti-CD20 treatment antibody Antibody Response applied blood test calculated Cancer cancer diagnosis cancer type cohort study diagnose dose doses English enzyme-linked immunosorbent Factor geometric mean titer hematologic Hispanic IgG IgG level Immunosuppressive treatment individual lowest lymphocyte lymphoid monoclonal antibody treatment morbidity and mortality mRNA-1273 Older outcome participant Patient patients treated Patients with cancer receipt receiving response SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 vaccine Seroconversion Seropositivity significantly lower small molecule solid tumor Spanish T Test treated Treatment vaccination vaccine dose vaccine response white [DOI] 10.1001/jamaoncol.2022.0001 PMC 바로가기 [Article Type] Article
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy항-CD20 치료 이력이 있는 환자에서 체액성 및 세포성 면역의 궤적과 SARS-CoV-2에 대한 3차 mRNA 백신에 대한 반응Article Published on 2022-03-012022-09-11 Journal: RMD Open [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] Analysis anti-CD20 anti-CD20 therapy anti-CD20 treatment anti-SARS-CoV-2 immune response anti-SARS-CoV-2 immune responses antibody concentration Antibody concentrations cell-mediated immune Cell-mediated immunity cellular immunity CMI comparable Concentration Control covariance COVID-19 decay dose elicited healthy volunteer healthy volunteers humoral humoral and cell-mediated immunity Humoral response humoral responses IgG immune responses Immunity immunogenicity inefficient interferon interferon-γ investigated Linear regression majority mRNA vaccine non-responder non-responders outcome Participants Patient patients registration number Responder responders response reveal rituximab RNA SARS-CoV-2 SARS-CoV-2 vaccine second vaccination systemic vasculitis Therapies therapy Trajectories trajectory Trial Registration Number vaccination Vaccination strategy Vaccine vaccine dose Vasculitis [DOI] 10.1136/rmdopen-2021-002166 PMC 바로가기 [Article Type] Article
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment항-CD20 단일클론항체는 치료 후 6개월 이내에 비호지킨 림프종 환자에서 Covid-19 예방접종에 대한 혈청양성 반응을 억제합니다Article Published on 2022-03-012022-09-12 Journal: Experimental hematology [Category] MERS, SARS, 진단, 치료법, [키워드] anti-CD20 anti-CD20 treatment B cell caused CD19 death Efficacy immunosuppressive indicated inhibit less lymphocyte lymphoma monoclonal antibodies monoclonal antibody Non-Hodgkin Lymphoma pandemic Patient Pfizer-BioNTech Prevent respond seropositive the healthy the vaccine therapy treated Treatment vaccination Vaccine volunteers [DOI] 10.1016/j.exphem.2021.12.396 PMC 바로가기 [Article Type] Article
Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature ReviewCase Report Published on 2022-02-252022-10-31 Journal: Case Reports in Infectious Diseases [Category] COVID-19, [키워드] acute respiratory syndrome addition anti-CD20 anti-CD20 treatment antibody Case report coronavirus Course COVID-19 Cycling Evidence expected Genotype Infection literature polymerase chain positive Reinfection report reverse transcription review rheumatoid arthritis RT-PCR SARS-CoV-2 Sequencing Seroconversion seropositive the disease threshold treated WGS whole genome [DOI] 10.1155/2022/8712424 PMC 바로가기 [Article Type] Case Report
Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 TreatmentsNeurology Published on 2022-02-232022-11-01 Journal: Frontiers in Neurology [Category] COVID-19, [키워드] Alter analysis of variance analyzed anti-CD20 monoclonal antibodies anti-CD20 treatment antibody Antibody Response Boston Central nervous system Characteristics Clinical characteristics CNS Cohort Community coronavirus disease COVID-19 COVID-19 antibody COVID-19 infection demonstrated demyelinating demyelinating disorder disease Disease modifying therapy Evidence Fisher Exact Humoral immunity IgG antibody immune system Immunity Infection infection risk lack less likelihood Logistic regression modulate multiple sclerosis Natalizumab nucleocapsid Patient patients Post-infection robust seropositive significantly higher significantly lower square subset Support the patient Treatment variables was performed with COVID-19 [DOI] 10.3389/fneur.2022.843081 PMC 바로가기 [Article Type] Neurology
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis다발성 경화증을 가진 회복기 COVID-19 환자의 SARS-CoV-2에 대한 체액 및 세포 반응Article Published on 2022-02-012022-09-11 Journal: Neurology® neuroimmunology & neuroinflammation [Category] MERS, 바이오마커, 진단, 치료법, [키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis anti-CD20 anti-CD20 therapy anti-CD20 treatment antibodies antibody Antibody testing Antibody titer Antibody titers cellular cellular response Characteristics convalescent coronavirus COVID-19 decrease demographics examined Factor humoral Humoral and cellular responses Humoral response IFN-γ Immunoglobulin Immunoglobulin G Interferon-gamma likelihood male Multiple multiple sclerosis Multivariate analysis not differ Nucleocapsid proteins Patient patients persistence producing progressive disease respiratory response Retrospective study SARS-CoV-2 SARS-CoV-2 antibody testing sclerosis seronegative patient seropositive Seropositivity severe acute respiratory syndrome Coronavirus severe COVID-19 therapy [DOI] 10.1212/NXI.0000000000001143 PMC 바로가기 [Article Type] Article
T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignanciesmRNA SARS-CoV-2 백신 후 T 세포 면역 반응은 림프 악성 종양 환자에서 혈청 전환이 없는 경우에도 자주 감지됩니다Clinical Trial Published on 2022-02-012022-09-12 Journal: British Journal of Haematology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] absence affected age and sex Analysis anti-cancer treatment anti-CD20 Anti-CD20 antibodies Anti-CD20 antibody anti-CD20 treatment antibody B-cell lymphoma cellular Chemotherapy treatment Complete conducted COVID-19 Diagnosis evaluated healthy subject Humoral response immune immune response Immunoglobulin increased mortality independent predictor lowest lymphoid lymphoid malignancies. lymphoma maintain malignancies malignancy Measures mRNA mRNA vaccination Multiple myeloma Patient Prospective Study Protective raise receiving Result SARS-CoV-2 vaccine Seroconversion seroconversion rate serological serological response seronegative patient subgroup of patient T-cell T-cell immune response T-cell Response Treatment vaccination [DOI] 10.1111/bjh.17877 PMC 바로가기 [Article Type] Clinical Trial
COVID-19 Vaccine Response in People with Multiple Sclerosis다발성 경화증 환자의 코로나19 백신 반응Article Published on 2022-01-012022-09-12 Journal: Annals of neurology [Category] MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval age ANN anti-CD20 anti-CD20 treatment anti-SARS-CoV-2 antibody Blood calculated cellular Cohort coronavirus disease COVID-19 disease drug drug history immune response Logistic regression Lymphocyte count management medical records medications monoclonal antibody Multiple multiple sclerosis not differ Odds ratio Patient predicted provided Quantitative questionnaire recommendation regression modeling response risk SARS-CoV-2 SARS-CoV-2 vaccination sclerosis Seroconversion serological response seronegative significantly subject T cell responses T-cell immunity tested the SARS-CoV-2 therapy Treatment vaccination Vaccine vaccine response [DOI] 10.1002/ana.26251 PMC 바로가기 [Article Type] Article
Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple SclerosisArticle Published on 2021-12-112022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] anti-CD20 therapy anti-CD20 treatment Antibody titer B cell depletion B-cell BNT162b2 vaccine CD20 clinically COVID-19 Depleted dose homologous humoral immune response IgG IgG antibody IgG response immunization individual infections lack median time Moderna mRNA mRNA vaccine mRNA-1273 mRNA-based vaccine Multiple outcome Patient Protective quantified response risk factor SARS-CoV-2 SARS-CoV-2 vaccine sclerosis Seroconversion seroconverted spike receptor-binding domain T-cell Response treated vaccination [DOI] 10.3390/vaccines9121470 PMC 바로가기 [Article Type] Article
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study암 환자에서 예방 접종 후 SARS-COV-2 변이체에 대한 적응 면역 및 중화 항체 : 캡처 연구Clinical Trial Published on 2021-11-232022-08-13 Journal: Nature cancer [Category] MERS, SARS, 바이오마커, 변종, 임상, 진단, 치료기술, 치료제, [키워드] Adaptive immunity Administered administration anti-CD20 anti-CD20 treatment Antibody Response Antibody titers AZD1222 BNT162b2 Cancer cancer patient Cancer patients cancers capture CAPTURE study comparable Concordance COVID-19 COVID-19 immunity COVID-19 pandemic detectable dose evaluated Hematological malignancies Hematological malignancy implication individuals without cancer malignancies malignancy management median nAb response NAb responses NAbT Neutralising Antibodies neutralizing antibody Neutralizing antibody titer of BNT162b2 Patient patients Patients with cancer patients with haematological proportion prospective cohort study Prospective Study reduced SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants Seroconversion seroconversion rates solid cancer solid cancers T-cell Response T-cell responses undetectable vaccination Vaccine Vaccine-induced T-cell response Vaccine-induced T-cell responses Vaccines VOCs wildtype [DOI] 10.1038/s43018-021-00274-w PMC 바로가기 [Article Type] Clinical Trial